Individualized therapy based on molecular alterations in gynecologic cancer
- Prosjektnummer
- 911874
- Ansvarlig person
- Jone Trovik
- Institusjon
- Helse Bergen HF
- Prosjektkategori
- Åpen prosjektstøtte
- Helsekategori
- Cancer
- Forskningsaktivitet
- 4. Detection and Diagnosis, 6. Treatment Evaluation
Brukerorganisasjonen for gynekologisk kreft har vært aktivt med ved prosjektplanlegging spesiselt for den del som omhandler persontilpasset operativ behandling: hvor omfattende operasjon som må gjøres (fjerne lymfeknuter eller ikke). Betydning av livskvalitetsregistrering er således blitt presisert av brukergruppen og tatt inn i prosjektet. Brukermedvirkning også mhp utvikling av instrument for nettbasert registrering av oppfølgningsdata inkludert livskvalitetsparametre.
APOBEC3A/B deletion polymorphism and endometrial cancer risk.
Cancer Med 2023 Mar;12(6):6659. Epub 2022 nov 16
PMID: 36394079
Mismatch repair markers in preoperative and operative endometrial cancer samples; expression concordance and prognostic value.
Br J Cancer 2023 Feb;128(4):647. Epub 2022 des 8
PMID: 36482191
Longitudinal effects of adjuvant chemotherapy and lymph node staging on patient-reported outcomes in endometrial cancer survivors: a prospective cohort study.
Am J Obstet Gynecol 2022 Jan;226(1):90.e1. Epub 2021 aug 13
PMID: 34400137
MRI-assessed tumor-free distance to serosa predicts deep myometrial invasion and poor outcome in endometrial cancer.
Insights Imaging 2022 Jan 08;13(1):1. Epub 2022 jan 8
PMID: 35000020
Integrated analysis of cervical squamous cell carcinoma cohorts from three continents reveals conserved subtypes of prognostic significance.
Nat Commun 2022 Oct 07;13(1):5818. Epub 2022 okt 7
PMID: 36207323
Interobserver agreement and prognostic impact for MRI-based 2018 FIGO staging parameters in uterine cervical cancer.
Eur Radiol 2022 Sep;32(9):6444. Epub 2022 mar 24
PMID: 35332408
What MRI-based tumor size measurement is best for predicting long-term survival in uterine cervical cancer?
Insights Imaging 2022 Jun 17;13(1):105. Epub 2022 jun 17
PMID: 35715582
Fully Automatic Whole-Volume Tumor Segmentation in Cervical Cancer.
Cancers (Basel) 2022 May 11;14(10). Epub 2022 mai 11
PMID: 35625977
A radiogenomics application for prognostic profiling of endometrial cancer.
Commun Biol 2021 12 06;4(1):1363. Epub 2021 des 6
PMID: 34873276
Risk Stratification of Endometrial Cancer Patients: FIGO Stage, Biomarkers and Molecular Classification.
Cancers (Basel) 2021 Nov 22;13(22). Epub 2021 nov 22
PMID: 34831000
A Gene Signature Identifying CIN3 Regression and Cervical Cancer Survival.
Cancers (Basel) 2021 Nov 16;13(22). Epub 2021 nov 16
PMID: 34830895
Genomic alterations associated with mutational signatures, DNA damage repair and chromatin remodeling pathways in cervical carcinoma.
NPJ Genom Med 2021 Oct 07;6(1):82. Epub 2021 okt 7
PMID: 34620846
Genomic Characterization and Therapeutic Targeting of HPV Undetected Cervical Carcinomas.
Cancers (Basel) 2021 Sep 10;13(18). Epub 2021 sep 10
PMID: 34572780
Feasibility and utility of MRI and dynamic
J Transl Med 2021 09 26;19(1):406. Epub 2021 sep 26
PMID: 34565386
Impact of hormonal biomarkers on response to hormonal therapy in advanced and recurrent endometrial cancer.
Am J Obstet Gynecol 2021 10;225(4):407.e1-407.e16. Epub 2021 mai 19
PMID: 34019887
Incorporating molecular profiling into endometrial cancer management requires prospective studies.
Int J Gynecol Cancer 2021 06;31(6):944-945. Epub 2021 mai 7
PMID: 33962995
Immunohistochemical biomarkers are prognostic relevant in addition to the ESMO-ESGO-ESTRO risk classification in endometrial cancer.
Gynecol Oncol 2021 06;161(3):787-794. Epub 2021 apr 12
PMID: 33858677
A 10-gene prognostic signature points to LIMCH1 and HLA-DQB1 as important players in aggressive cervical cancer disease.
Br J Cancer 2021 05;124(10):1690-1698. Epub 2021 mar 15
PMID: 33723390
An MRI-Based Radiomic Prognostic Index Predicts Poor Outcome and Specific Genetic Alterations in Endometrial Cancer.
J Clin Med 2021 Feb 02;10(3). Epub 2021 feb 2
PMID: 33540589
Nuclear upregulation of class I phosphoinositide 3-kinase p110β correlates with high 47S rRNA levels in cancer cells.
J Cell Sci 2021 02 10;134(3). Epub 2021 feb 10
PMID: 33536247
Automated segmentation of endometrial cancer on MR images using deep learning.
Sci Rep 2021 01 08;11(1):179. Epub 2021 jan 8
PMID: 33420205
Maintained survival outcome after reducing lymphadenectomy rates and optimizing adjuvant treatment in endometrial cancer.
Gynecol Oncol 2021 02;160(2):396-404. Epub 2020 des 13
PMID: 33317908
Whole-Volume Tumor MRI Radiomics for Prognostic Modeling in Endometrial Cancer.
J Magn Reson Imaging 2021 03;53(3):928-937. Epub 2020 nov 16
PMID: 33200420
Cancer awareness in the general population varies with sex, age and media coverage: A population-based survey with focus on gynecologic cancers.
Eur J Obstet Gynecol Reprod Biol 2021 Jan;256():25-31. Epub 2020 nov 1
PMID: 33161211
Tumour texture features from preoperative CT predict high-risk disease in endometrial cancer.
Clin Radiol 2021 01;76(1):79.e13-79.e20. Epub 2020 sep 14
PMID: 32938538
Mendelian randomization analyses suggest a role for cholesterol in the development of endometrial cancer.
Int J Cancer 2021 01 15;148(2):307-319. Epub 2020 aug 7
PMID: 32851660
Salvage Radiation for Pelvic Relapse after Surgically Treated Endometrial Cancer.
Cancers (Basel) 2021 Mar 18;13(6). Epub 2021 mar 18
PMID: 33803531
Prognostic Value of the Diversity of Nuclear Chromatin Compartments in Gynaecological Carcinomas.
Cancers (Basel) 2020 Dec 19;12(12). Epub 2020 des 19
PMID: 33352679
Preoperative risk stratification in endometrial cancer (ENDORISK) by a Bayesian network model: A development and validation study.
PLoS Med 2020 05;17(5):e1003111. Epub 2020 mai 15
PMID: 32413043
Development of prediction models for lymph node metastasis in endometrioid endometrial carcinoma.
Br J Cancer 2020 03;122(7):1014-1022. Epub 2020 feb 10
PMID: 32037399
Preoperative 18F-FDG PET/CT tumor markers outperform MRI-based markers for the prediction of lymph node metastases in primary endometrial cancer.
Eur Radiol 2020 May;30(5):2443-2453. Epub 2020 feb 7
PMID: 32034487
High degree of heterogeneity of PD-L1 and PD-1 from primary to metastatic endometrial cancer.
Gynecol Oncol 2020 04;157(1):260-267. Epub 2020 jan 21
PMID: 31973911
Blood steroid levels predict survival in endometrial cancer and reflect tumor estrogen signaling.
Gynecol Oncol 2020 02;156(2):400-406. Epub 2019 des 6
PMID: 31813586
Fertility-sparing treatment in early endometrial cancer: current state and future strategies.
Obstet Gynecol Sci 2020 Jul;63(4):417-431. Epub 2020 jul 8
PMID: 32689770
Improving response to progestin treatment of low-grade endometrial cancer.
Int J Gynecol Cancer 2020 Nov;30(11):1811-1823. Epub 2020 mai 6
PMID: 32381512
Near-Infrared Fluorescent Imaging for Monitoring of Treatment Response in Endometrial Carcinoma Patient-Derived Xenograft Models.
Cancers (Basel) 2020 Feb 06;12(2). Epub 2020 feb 6
PMID: 32041116
Amplification Associates with Aggressive Phenotype but Not Markers of AKT-MTOR Signaling in Endometrial Carcinoma.
Clin Cancer Res 2019 01 01;25(1):334-345. Epub 2018 nov 15
PMID: 30442683
Blood steroids are associated with prognosis and fat distribution in endometrial cancer.
Gynecol Oncol 2019 01;152(1):46-52. Epub 2018 okt 26
PMID: 30554934
Addition of IMP3 to L1CAM for discrimination between low- and high-grade endometrial carcinomas: a European Network for Individualised Treatment of Endometrial Cancer collaboration study.
Hum Pathol 2019 Jul;89():90-98. Epub 2019 mai 3
PMID: 31054899
Poor outcome in hypoxic endometrial carcinoma is related to vascular density.
Br J Cancer 2019 May;120(11):1037-1044. Epub 2019 apr 23
PMID: 31011231
Blood Metabolites Associate with Prognosis in Endometrial Cancer.
Metabolites 2019 Dec 14;9(12). Epub 2019 des 14
PMID: 31847385
Plasma growth differentiation factor-15 is an independent marker for aggressive disease in endometrial cancer.
PLoS One 2019;14(1):e0210585. Epub 2019 jan 15
PMID: 30645608
Novel PCDH10-Wnt-MALAT1 regulatory axis in endometrioid endometrial adenocarcinoma.
Hong Kong Med J 2019 Oct;25 Suppl 7(5):17-22.
PMID: 31761765
High expression of the p53 isoform γ is associated with reduced progression-free survival in uterine serous carcinoma.
BMC Cancer 2018 Jun 25;18(1):684. Epub 2018 jun 25
PMID: 29940909
Preoperative quantitative dynamic contrast-enhanced MRI and diffusion-weighted imaging predict aggressive disease in endometrial cancer.
Acta Radiol 2018 Aug;59(8):1010-1017. Epub 2017 nov 14
PMID: 29137496
Asparaginase-like protein 1 expression in curettage independently predicts lymph node metastasis in endometrial carcinoma: a multicentre study.
BJOG 2018 Dec;125(13):1695-1703. Epub 2018 aug 19
PMID: 29989298
Asparaginase-like protein 1 is an independent prognostic marker in primary endometrial cancer, and is frequently lost in metastatic lesions.
Gynecol Oncol 2018 01;148(1):197-203. Epub 2017 okt 31
PMID: 29096882
Chromatin organisation and cancer prognosis: a pan-cancer study.
Lancet Oncol 2018 03;19(3):356-369. Epub 2018 feb 3
PMID: 29402700
Blocking 17β-hydroxysteroid dehydrogenase type 1 in endometrial cancer: a potential novel endocrine therapeutic approach.
J Pathol 2018 Feb;244(2):203-214. Epub 2018 jan 3
PMID: 29144553
Development of an Image-Guided Orthotopic Xenograft Mouse Model of Endometrial Cancer with Controllable Estrogen Exposure.
Int J Mol Sci 2018 Aug 28;19(9). Epub 2018 aug 28
PMID: 30154339
Identification of highly connected and differentially expressed gene subnetworks in metastasizing endometrial cancer.
PLoS One 2018;13(11):e0206665. Epub 2018 nov 1
PMID: 30383835
Class I Phosphoinositide 3-Kinase
Int J Mol Sci 2018 Dec 07;19(12). Epub 2018 des 7
PMID: 30544563
Patient-Derived Xenograft Models for Endometrial Cancer Research.
Int J Mol Sci 2018 Aug 17;19(8). Epub 2018 aug 17
PMID: 30126113
Association Between Proportion of Nuclei With High Chromatin Entropy and Prognosis in Gynecological Cancers.
J Natl Cancer Inst 2018 Dec 01;110(12):1400-1408.
PMID: 29684152
Genetic overlap between endometriosis and endometrial cancer: evidence from cross-disease genetic correlation and GWAS meta-analyses.
Cancer Med 2018 May;7(5):1978-1987. Epub 2018 apr 2
PMID: 29608257
Added Value of Estrogen Receptor, Progesterone Receptor, and L1 Cell Adhesion Molecule Expression to Histology-Based Endometrial Carcinoma Recurrence Prediction Models: An ENITEC Collaboration Study.
Int J Gynecol Cancer 2018 03;28(3):514-523.
PMID: 29324536
L1CAM expression in uterine carcinosarcoma is limited to the epithelial component and may be involved in epithelial-mesenchymal transition.
Virchows Arch 2018 Nov;473(5):591-598. Epub 2018 aug 23
PMID: 30140948
Preoperative tumor texture analysis on MRI predicts high-risk disease and reduced survival in endometrial cancer.
J Magn Reson Imaging 2018 Dec;48(6):1637-1647. Epub 2018 aug 13
PMID: 30102441
HER2 expression patterns in paired primary and metastatic endometrial cancer lesions.
Br J Cancer 2018 02 06;118(3):378-387. Epub 2017 nov 23
PMID: 29169184
In vivo MR spectroscopy predicts high tumor grade in endometrial cancer.
Acta Radiol 2018 Apr;59(4):497-505. Epub 2017 sep 19
PMID: 28927296
Tumour-microenvironmental blood flow determines a metabolomic signature identifying lysophospholipids and resolvin D as biomarkers in endometrial cancer patients.
Oncotarget 2017 Dec 12;8(65):109018-109026. Epub 2017 nov 20
PMID: 29312587
Proteomic profiling of endometrioid endometrial cancer reveals differential expression of hormone receptors and MAPK signaling proteins in obese versus non-obese patients.
Oncotarget 2017 Dec 05;8(63):106989-107001. Epub 2017 okt 31
PMID: 29291005
High visceral fat percentage is associated with poor outcome in endometrial cancer.
Oncotarget 2017 Dec 01;8(62):105184-105195. Epub 2017 okt 19
PMID: 29285243
Preoperative imaging markers and PDZ-binding kinase tissue expression predict low-risk disease in endometrial hyperplasias and low grade cancers.
Oncotarget 2017 Sep 15;8(40):68530-68541. Epub 2017 jul 31
PMID: 28978135
Type of vascular invasion in association with progress of endometrial cancer.
APMIS 2017 Dec;125(12):1084-1091. Epub 2017 okt 4
PMID: 28975668
Expression of glucocorticoid receptor is associated with aggressive primary endometrial cancer and increases from primary to metastatic lesions.
Gynecol Oncol 2017 12;147(3):672-677. Epub 2017 sep 18
PMID: 28927900
PIK3CA exon9 mutations associate with reduced survival, and are highly concordant between matching primary tumors and metastases in endometrial cancer.
Sci Rep 2017 Aug 31;7(1):10240. Epub 2017 aug 31
PMID: 28860563
Late-week surgical treatment of endometrial cancer is associated with worse long-term outcome: Results from a prospective, multicenter study.
PLoS One 2017;12(8):e0182223. Epub 2017 aug 3
PMID: 28771617
Expression of L1CAM in curettage or high L1CAM level in preoperative blood samples predicts lymph node metastases and poor outcome in endometrial cancer patients.
Br J Cancer 2017 Sep 05;117(6):840-847. Epub 2017 jul 27
PMID: 28751757
Clinicopathologic and molecular markers in cervical carcinoma: a prospective cohort study.
Am J Obstet Gynecol 2017 10;217(4):432.e1-432.e17. Epub 2017 jun 24
PMID: 28599900
Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas-an ENITEC Group Initiative.
Clin Cancer Res 2017 Mar 01;23(5):1274-1285.
PMID: 28232476
Aneuploidy related transcriptional changes in endometrial cancer link low expression of chromosome 15q genes to poor survival.
Oncotarget 2017 Feb 07;8(6):9696-9707.
PMID: 28039471
Changes in Chromatin Structure in Curettage Specimens Identifies High-Risk Patients in Endometrial Cancer.
Cancer Epidemiol Biomarkers Prev 2017 Jan;26(1):61-67. Epub 2016 sep 1
PMID: 27587790
Harmonisation of biobanking standards in endometrial cancer research.
Br J Cancer 2017 Aug 08;117(4):485-493. Epub 2017 jun 29
PMID: 28664917
Endometrial cancer cells exhibit high expression of p110β and its selective inhibition induces variable responses on PI3K signaling, cell survival and proliferation.
Oncotarget 2017 Jan 17;8(3):3881-3894.
PMID: 28002804
High mRNA levels of 17β-hydroxysteroid dehydrogenase type 1 correlate with poor prognosis in endometrial cancer.
Mol Cell Endocrinol 2017 Feb 15;442():51-57. Epub 2016 des 5
PMID: 27923582
Increased microvascular permeability in mice lacking Epac1 (Rapgef3).
Acta Physiol (Oxf) 2017 Feb;219(2):441-452. Epub 2016 mai 17
PMID: 27096875
Epac1-deficient mice have bleeding phenotype and thrombocytes with decreased GPIbβ expression.
Sci Rep 2017 Aug 18;7(1):8725. Epub 2017 aug 18
PMID: 28821815
Genetic Risk Score Mendelian Randomization Shows that Obesity Measured as Body Mass Index, but not Waist:Hip Ratio, Is Causal for Endometrial Cancer.
Cancer Epidemiol Biomarkers Prev 2016 Nov;25(11):1503-1510. Epub 2016 aug 22
PMID: 27550749
Tissue and imaging biomarkers for hypoxia predict poor outcome in endometrial cancer.
Oncotarget 2016 Oct 25;7(43):69844-69856.
PMID: 27634881
Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study.
Int J Epidemiol 2016 Oct;45(5):1619-1630. Epub 2016 sep 4
PMID: 27594614
L1CAM expression in endometrial carcinomas: an ENITEC collaboration study.
Br J Cancer 2016 Sep 06;115(6):716-24. Epub 2016 aug 9
PMID: 27505134
Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study.
Int J Epidemiol 2016 Jun;45(3):884-95. Epub 2016 jul 10
PMID: 27401727
Androgen receptor as potential therapeutic target in metastatic endometrial cancer.
Oncotarget 2016 Aug 02;7(31):49289-49298.
PMID: 27384477
The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis.
Nat Genet 2016 Aug;48(8):848-55. Epub 2016 jun 27
PMID: 27348297
Corrigendum: Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth.
Sci Rep 2016 Jun 24;6():27960. Epub 2016 jun 24
PMID: 27338572
A Common Variant at the 14q32 Endometrial Cancer Risk Locus Activates AKT1 through YY1 Binding.
Am J Hum Genet 2016 Jun 02;98(6):1159-69.
PMID: 27259051
Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth.
Sci Rep 2016 May 10;6():25521. Epub 2016 mai 10
PMID: 27160768
Five endometrial cancer risk loci identified through genome-wide association analysis.
Nat Genet 2016 Jun;48(6):667-74. Epub 2016 mai 2
PMID: 27135401
Assessing the genetic architecture of epithelial ovarian cancer histological subtypes.
Hum Genet 2016 Jul;135(7):741-56. Epub 2016 apr 13
PMID: 27075448
What Is the Best Preoperative Imaging for Endometrial Cancer?
Curr Oncol Rep 2016 Apr;18(4):25.
PMID: 26922331
The MDM4 SNP34091 (rs4245739) C-allele is associated with increased risk of ovarian-but not endometrial cancer.
Tumour Biol 2016 Aug;37(8):10697-702. Epub 2016 feb 11
PMID: 26867771
High Diagnostic Value of 18F-FDG PET/CT in Endometrial Cancer: Systematic Review and Meta-Analysis of the Literature.
J Nucl Med 2016 Jun;57(6):879-85. Epub 2016 jan 28
PMID: 26823564
CYP19A1 fine-mapping and Mendelian randomization: estradiol is causal for endometrial cancer.
Endocr Relat Cancer 2016 Feb;23(2):77-91. Epub 2015 nov 16
PMID: 26574572
Integrative Protein-Based Prognostic Model for Early-Stage Endometrioid Endometrial Cancer.
Clin Cancer Res 2016 Jan 15;22(2):513-23. Epub 2015 jul 29
PMID: 26224872
Intra-Gene DNA Methylation Variability Is a Clinically Independent Prognostic Marker in Women's Cancers.
PLoS One 2015;10(12):e0143178. Epub 2015 des 2
PMID: 26629914
Meta-analysis of genome-wide association studies identifies common susceptibility polymorphisms for colorectal and endometrial cancer near SH2B3 and TSHZ1.
Sci Rep 2015;5():17369. Epub 2015 des 1
PMID: 26621817
HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer.
Genome Med 2015;7(1):108. Epub 2015 okt 24
PMID: 26497652
Tumor necrosis is an important hallmark of aggressive endometrial cancer and associates with hypoxia, angiogenesis and inflammation responses.
Oncotarget 2015 Nov 24;6(37):39676-91.
PMID: 26485755
Correlation of Smoking-Associated DNA Methylation Changes in Buccal Cells With DNA Methylation Changes in Epithelial Cancer.
JAMA Oncol 2015 Jul;1(4):476-85.
PMID: 26181258
Genome-wide significant risk associations for mucinous ovarian carcinoma.
Nat Genet 2015 Aug;47(8):888-97. Epub 2015 jun 15
PMID: 26075790
PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patients.
Mol Oncol 2015 Oct;9(8):1694-703. Epub 2015 mai 16
PMID: 26045339
Metabolic Tumor Volume on 18F-FDG PET/CT Improves Preoperative Identification of High-Risk Endometrial Carcinoma Patients.
J Nucl Med 2015 Aug;56(8):1191-8. Epub 2015 jun 4
PMID: 26045311
DNA ploidy in curettage specimens identifies high-risk patients and lymph node metastasis in endometrial cancer.
Br J Cancer 2015 May 12;112(10):1656-64. Epub 2015 apr 21
PMID: 25897678
Increased angiogenesis is associated with a 32-gene expression signature and 6p21 amplification in aggressive endometrial cancer.
Oncotarget 2015 Apr 30;6(12):10634-45.
PMID: 25860936
Loss of ASRGL1 expression is an independent biomarker for disease-specific survival in endometrioid endometrial carcinoma.
Gynecol Oncol 2015 Jun;137(3):529-37. Epub 2015 apr 7
PMID: 25858696
Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci.
Hum Mol Genet 2015 Jul 1;24(13):3595-607. Epub 2015 mar 24
PMID: 25804953
Tumour apparent diffusion coefficient is associated with depth of myometrial invasion and is negatively correlated to tumour volume in endometrial carcinomas.
Clin Radiol 2015 May;70(5):487-94. Epub 2015 jan 30
PMID: 25639620
Preoperative tumor size at MRI predicts deep myometrial invasion, lymph node metastases, and patient outcome in endometrial carcinomas.
Int J Gynecol Cancer 2015 Mar;25(3):459-66.
PMID: 25628109
Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients.
Oncotarget 2015 Jan 20;6(2):1327-39.
PMID: 25415225
Fine-mapping of the HNF1B multicancer locus identifies candidate variants that mediate endometrial cancer risk.
Hum Mol Genet 2015 Mar 1;24(5):1478-92. Epub 2014 nov 6
PMID: 25378557
Landscape of genomic alterations in cervical carcinomas.
Nature 2014 Feb 20;506(7488):371-5. Epub 2013 des 25
PMID: 24390348
Growth differentiation factor-15 as biomarker in uterine sarcomas.
Int J Gynecol Cancer 2014 Feb;24(2):252-9.
PMID: 24401984
Clinical value of DNA content assessment in endometrial cancer.
Cytometry B Clin Cytom 2014 May;86(3):154-63. Epub 2014 feb 14
PMID: 24532190
Stathmin protein level, a potential predictive marker for taxane treatment response in endometrial cancer.
PLoS One 2014;9(2):e90141. Epub 2014 feb 25
PMID: 24587245
Hypomethylation of the CTCFL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epi-driver gene.
Oncotarget 2014 Feb 28;5(4):1052-61.
PMID: 24658009
Switch in FOXA1 status associates with endometrial cancer progression.
PLoS One 2014;9(5):e98069. Epub 2014 mai 21
PMID: 24849812
High level of HSF1 associates with aggressive endometrial carcinoma and suggests potential for HSP90 inhibitors.
Br J Cancer 2014 Jul 8;111(1):78-84. Epub 2014 mai 22
PMID: 24853175
Endometrial Carcinoma Recurrence Score (ECARS) validates to identify aggressive disease and associates with markers of epithelial-mesenchymal transition and PI3K alterations.
Gynecol Oncol 2014 Sep;134(3):599-606. Epub 2014 jul 1
PMID: 24995579
Current status of molecular biomarkers in endometrial cancer.
Curr Oncol Rep 2014 Sep;16(9):403.
PMID: 25064587
A novel wnt regulatory axis in endometrioid endometrial cancer.
Cancer Res 2014 Sep 15;74(18):5103-17. Epub 2014 aug 1
PMID: 25085246
Molecular profiling in fresh tissue with high tumor cell content promotes enrichment for aggressive adenocarcinomas in cervix.
Pathol Res Pract 2014 Nov;210(11):774-8. Epub 2014 jul 22
PMID: 25123963
Annexin-A2 as predictor biomarker of recurrent disease in endometrial cancer.
Int J Cancer 2014 Sep 13. Epub 2014 sep 13
PMID: 25219463
Molecular profiling of circulating tumor cells links plasticity to the metastatic process in endometrial cancer.
Mol Cancer 2014;13():223. Epub 2014 sep 27
PMID: 25261936
Loss of progesterone receptor links to high proliferation and increases from primary to metastatic endometrial cancer lesions.
Eur J Cancer 2014 Nov;50(17):3003-10. Epub 2014 sep 30
PMID: 25281525
Fertility and gonadal function after adjuvant therapy in women diagnosed with a malignant ovarian germ cell tumor (MOGCT) during the "cisplatin era".
Gynecol Oncol 2015 Feb;136(2):224-9. Epub 2014 des 12
PMID: 25511159
Organoid models and novel biomarkers for improved treatment of endometrial cancer
- Disputert:
- april 2022
- Hovedveileder:
- Camilla Krakstad
Novel preoperative biomarkers and evaluation of altered treatment strategies to improve outcome for endometrial cancer patients
- Disputert:
- oktober 2021
- Hovedveileder:
- Camilla Krakstad
Molecular markers to predict prognosis and guide therapy in endometrial cancer
- Disputert:
- februar 2020
- Hovedveileder:
- Camilla Krakstad
Preclinical models and molecular biomarkers tools to improve treatmentin endometrial carcinoma
- Disputert:
- november 2018
- Hovedveileder:
- Camilla Krakstad
Context-related biomarkers in endometrial cancer
- Disputert:
- juni 2017
- Hovedveileder:
- Henrica Maria Johanna Werner
Molecular alteratiohns and diagnostic imaging in premalignant and malignant endometrial lesions
- Disputert:
- juni 2017
- Hovedveileder:
- Ingfrid S Haldorsen
Molecular alterations suggesting new treatment strategies in uterine carcinomas
- Disputert:
- november 2017
- Hovedveileder:
- Camilla Krakstad
Functional imaging to promote individualized and targeted
- Disputert:
- februar 2016
- Hovedveileder:
- Ingfrid S Haldorsen
Hormone signaling related factors as biomarkers in endometrial cancer
- Disputert:
- oktober 2016
- Hovedveileder:
- Camilla Krakstad
Clinical and molecular markers in endometrial cancer.
- Disputert:
- mai 2014
- Hovedveileder:
- Helga Birgitte Salvesen
- David Erik Forsse Ph.d.-kandidat
- Olivera Bozickovic Prosjektdeltaker
- Kathrine Woie Prosjektdeltaker
- Tina Fonnes Ph.d.-kandidat
- Line Bjørge Prosjektdeltaker
- Karen Klepsland Mauland Prosjektdeltaker
- Kadri Madissoo Prosjektdeltaker
- Vikram Rao Bollineni Prosjektdeltaker
- Elisabeth Berge Nilsen Prosjektdeltaker
- Nina Nordskar Prosjektdeltaker
- Klaus Oddenes Prosjektdeltaker
- Jone Trovik Prosjektleder
- Camilla Krakstad Leder av forskningsgruppe
- Henrica Maria Johanna Werner Postdoktor
- Erling Andre Høivik Postdoktor
- Ingvild Løberg Tangen Postdoktor
- Mari Kyllesø Halle Postdoktor
- Hilde Renate Haugen Engerud Ph.d.-kandidat
- Ingfrid S Haldorsen Prosjektdeltaker
- Solveig Kristi Tingulstad Prosjektdeltaker
- Ivar Jostein Tjugum Prosjektdeltaker
- Ellen Valen Prosjektdeltaker
- Siv Mjøs Prosjektdeltaker
- Reidun Kristin Kopperud Prosjektdeltaker
- Britt Edvardsen Prosjektdeltaker
- Sigmund Ytre-Hauge Ph.d.-kandidat
- Jenny Hild Aase Husby Ph.d.-kandidat
- Helga Birgitte Salvesen Prosjektleder
- Therese Bredholt Onyango Postdoktor
- Kanthida Kusonmano Prosjektdeltaker
- Frederik Holst Postdoktor
- Anna Berg Ph.d.-kandidat
eRapport er utarbeidet av Sølvi Lerfald og Reidar Thorstensen, Regionalt kompetansesenter for klinisk forskning, Helse Vest RHF, og videreutvikles av de fire RHF-ene i fellesskap, med støtte fra Helse Vest IKT
Alle henvendelser rettes til Faglig rapportering, Helse Vest